Análise final da sobrevida geral do estudo randomizado HER2CLIMB: tucatinibe vs. placebo adicionado a trastuzumabe e capecitabina para pacientes com câncer de mama metastático HER2+ tratado previamente com ou sem metástases cerebrais.
13 Jan, 2022 | 20:42hTucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis – Annals of Oncology (link para o resumo – $ para o texto completo)
Estudo original: Randomized Trial: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer